MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for See below for a list of each quarter's courses. Click here to visit MPR's website.

Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits
Clinical Review

New Drug Review from MPR (October 2013)

1.00 Credits

Archived CME/CE Courses


MPR Drug News

Mylan Launches Generic Viramune XR

Mylan announced that the Food and Drug Administration (FDA) has approved Nevirapine Extended-Release Tablets, the generic version of Boehringer Ingelheim's Viramune XR.

NBI-98854 Designated Breakthrough Therapy for Tardive Dyskinesia

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for NBI-98854 (Neurocrine Biosciences) for tardive dyskinesia.

Investigational Gene Therapy Designated Orphan Drug for Eye Disorder

The Food and Drug Administration (FDA) has granted Orphan Drug designation to RST-001 for the treatment of retinitis pigmentosa (RP).

TWi Approved for Generic Aricept

TWi Pharmaceuticals announced it has received final approval from the Food and Drug Administration (FDA) for Donepezil HCl Tablets, the generic version of Eisai's Aricept.

Xigduo XR Approved for Type 2 Diabetes

AstraZeneca announced that the FDA has approved Xigduo XR (dapagliflozin and metformin HCl extended-release) for adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.